Eastern Cooperative Oncology Group

描述(由申请人提供)：贝丝以色列女执事医疗中心(BIDMC)是1996年贝丝以色列和新英格兰女执事医院、两个邻居和位于朗伍德医疗区的主要哈佛医学院机构合并而成的。BIDMC的教职员工由一群敬业的基础和临床研究人员组成。BIDMC是全国公认的以疾病为基础的特殊专业中心的所在地，包括那些专注于乳腺癌、黑色素瘤、肾癌、前列腺癌和肝脏恶性肿瘤的中心。BIDMC调查人员是关注乳腺癌、皮肤癌、肾癌、前列腺癌和肺癌的孢子赠款的积极参与者。著名的科学专长领域包括：疫苗和细胞因子治疗、血管生成和信号转导抑制。1999年，BIDMC参与创建了Dana-Farber/哈佛癌症中心，该中心包括所有哈佛医学院附属机构：BIDMC、Dana-Farber癌症研究所、布里格姆妇女医院、马萨诸塞州综合医院、儿童医院医学中心、哈佛医学院和哈佛公共卫生学院。DF/HCC的形成将极大地提高获得ECOG和CTSU试验的能力。 BIDMC自1997年以来一直是ECOG的主要机构，非常致力于临床研究。在过去的五年中，BIDMC每年持续招募50多名患者参加治疗和预防试验。从1998年1月到2002年12月，BIDMC已经成功招募了310多名患者。到目前为止，在2003年，BIDMC已经招募了43名患者。为了促进成功的患者登记，BIDMC大幅增加了在ECOG试验中工作的数据经理、护士和支持人员的数量。 我们致力于进一步发展我们在实验室和临床研究方面的发展，并增加我们对EOCG的行政参与。

DESCRIPTION (provided by applicant): Beth Israel Deaconess Medical Center (BIDMC) resulted from the 1996 merger of the Beth Israel and New England Deaconess Hospitals, two neighbors and major Harvard Medical School Institutions in the Longwood Medical area. The BIDMC faculty consists of an exceptional group of committed basic and clinical researchers. BIDMC is home to nationally recognized diseased-based centers of special expertise including those focusing on breast cancer, melanoma, renal cancer, prostate cancer and hepatic malignancies. BIDMC investigators are active participants in SPORE grants focused on Breast, Skin, Renal, Prostate and Lung Cancers. Areas of renowned scientific expertise include: vaccine and cytokine therapy, angiogenesis and signal transduction inhibition. In 1999, the BIDMC participated in the founding of the Dana-Farber/Harvard Cancer Center (DF/HCC), which includes all Harvard Medical School affiliated institutions: BIDMC, Dana-Farber Cancer Institute, Brigham and Woman's Hospital, Massachusetts General Hospital, Children's Hospital Medical Center, Harvard Medical School and Harvard School of Public Health. The formation of DF/HCC will greatly enhance the ability to accrue to ECOG and CTSU trials. BIDMC has been a main ECOG Institution since 1997 and is very committed to clinical research. Over the last five years BIDMC has consistently recruited over 50 patients to therapeutic and prevention trials a year. BIDMC has successfully enrolled over 310 patients from January 1998 to December 2002. To date, in 2003, BIDMC has recruited 43 patients. In order to facilitate successful patient enrollment, BIDMC has significantly increased the number of data managers, nurses and support staff working on ECOG trials. We are committed to further our growth in laboratory and clinical research and increase our administrative participation in EOCG.